Leerink Partnrs Analysts Raise Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Leerink Partnrs raised their Q2 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Monday, May 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($1.21) per share for the quarter, up from their prior forecast of ($1.22). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' Q3 2025 earnings at ($1.24) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($4.39) EPS, FY2027 earnings at $3.15 EPS, FY2028 earnings at $9.25 EPS and FY2029 earnings at $15.40 EPS.

Several other brokerages also recently issued reports on AXSM. Royal Bank of Canada raised their price target on Axsome Therapeutics from $190.00 to $193.00 and gave the company an "outperform" rating in a research report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price target for the company. Mizuho boosted their price objective on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a report on Thursday, March 27th. HC Wainwright decreased their target price on Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating on the stock in a research report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $153.00 price target on shares of Axsome Therapeutics in a report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $172.14.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM traded down $1.10 during trading hours on Thursday, hitting $107.76. 435,267 shares of the stock were exchanged, compared to its average volume of 682,708. The firm has a market capitalization of $5.31 billion, a P/E ratio of -17.99 and a beta of 0.46. Axsome Therapeutics has a one year low of $64.11 and a one year high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The company's 50 day moving average is $112.01 and its 200 day moving average is $104.59.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its position in shares of Axsome Therapeutics by 14.9% during the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock worth $19,062,000 after purchasing an additional 27,534 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in Axsome Therapeutics in the 4th quarter valued at $2,599,000. Intech Investment Management LLC increased its stake in shares of Axsome Therapeutics by 46.5% in the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company's stock valued at $1,356,000 after buying an additional 5,087 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Axsome Therapeutics during the fourth quarter worth $14,771,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Axsome Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock valued at $27,755,000 after acquiring an additional 5,438 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.